# Sitagliptin With Pembro in RCC and Melanoma

> **NCT07634380** · PHASE1 · RECRUITING · sponsor: **Fernando Maciel Barbosa** · enrollment: 64 (estimated)

## Conditions studied

- Advanced Renal Cell Carcinoma
- Advanced Melanoma

## Interventions

- **DRUG:** Sitagliptin
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07634380
- **Lead sponsor:** Fernando Maciel Barbosa
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-14
- **Primary completion:** 2028-04-10
- **Final completion:** 2031-04-10
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07634380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07634380, "Sitagliptin With Pembro in RCC and Melanoma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07634380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*